US · APM
Aptorum Group Limited
- Sector
- Healthcare · Biotechnology
- Headquarters
- London W1S 1BN
- Website
- aptorumgroup.com
Price · as of 2024-12-31
$0.88
Market cap 4.95M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $241.12 | +27,296.89% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $143.20 | ||||
| 2019 | $41.20 | $35.83 | $0.00 | $0.00 | $0.00 |
| 2020 | $32.60 | $82.93 | $3.46 | $21.14 | $171.27 |
| 2021 | $13.10 | $266.41 | $0.00 | $0.00 | $0.00 |
| 2022 | $2.74 | $54.77 | $0.00 | $0.00 | $19.70 |
| 2023 | $6.88 | $135.23 | $1.45 | $2.37 | $34.85 |
| 2024 | $0.94 | $241.12 |
AI valuation
Our deep-learning model estimates Aptorum Group Limited's (APM) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $241.12
- Current price
- $0.88
- AI upside
- +27,296.89%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| APM | Aptorum Group Limited | $0.88 | 4.95M | +27,297% | — | — | — | -1.20 | 0.24 | — | -2.03 | -4.65 | 0.24 | 0.00% | — | — | -18.56% | -15.20% | -23.21% | 0.16 | -25.84 | 0.22 | 0.20 | -0.66 | 2581.00% | -10000.00% | -8459.00% | -23.24% | -0.27 | -4.77% | 0.00% | 0.00% | 0.00% | -2.00 | -6.39 | — | -6.61 |
| BOLT | Bolt Biotherapeutics, Inc… | $4.52 | 8.68M | +449% | -22% | — | — | -5.28 | 5.82 | 43.30 | -4.68 | — | 5.82 | 100.00% | -949.91% | -820.78% | -74.28% | -221.84% | -48.66% | 0.44 | — | 3.20 | 3.06 | -0.27 | -984.00% | -236.00% | -1205.00% | -18.42% | -3.87 | -186.26% | 0.00% | 0.00% | 0.00% | -4.26 | -5.07 | 40.42 | -3.22 |
| CING | Cingulate Inc. | $6.27 | 35.15M | — | — | — | — | -0.95 | 1.97 | — | -0.51 | — | 1.97 | 0.00% | — | — | -5305.02% | 1019.77% | -169.38% | 0.68 | — | 2.55 | 2.46 | 0.48 | -9673.00% | — | 2231.00% | -126.84% | -3.71 | 1216.50% | 0.00% | 0.00% | 71.84% | -0.49 | -0.41 | — | -11.88 |
| CLRB | Cellectar Biosciences, In… | $3.25 | 10.36M | — | — | — | — | -0.26 | 0.82 | — | 0.22 | — | 0.82 | 0.00% | — | — | -17221.69% | 330.97% | -237.45% | 0.03 | — | 2.58 | 2.48 | 0.44 | -6010.00% | — | 4346.00% | -406.92% | -5.07 | 304.82% | 0.00% | 0.00% | 117.61% | 0.21 | 0.23 | — | -18.97 |
| COCP | Cocrystal Pharma, Inc. | $1.05 | 10.76M | — | — | — | — | -0.99 | 1.82 | — | -0.52 | 0.00 | 1.82 | 0.00% | — | — | -97.50% | -1066.39% | -78.29% | 0.19 | — | 4.77 | 4.56 | 0.45 | 9042632.00% | — | 1156.00% | -95.36% | -6.79 | -983.78% | 0.00% | 0.00% | 0.00% | -0.52 | -0.56 | — | -35.62 |
| EVGN | Evogene Ltd. | $0.88 | 7.65M | +2,548% | -33% | — | — | -0.47 | -5.81 | 0.99 | -0.39 | — | -0.62 | 39.81% | -255.36% | -193.69% | -340.58% | 381.57% | -39.69% | -8.87 | -175.27 | 1.15 | 0.90 | 0.16 | -4474.00% | 5090.00% | -910.00% | -241.06% | -1.05 | 356.85% | 0.00% | 0.00% | 0.00% | -0.28 | -0.29 | 0.70 | -10.92 |
| IMRN | Immuron Limited | $0.77 | 4.96M | +2,352% | +18,330% | — | — | -3.14 | 2.04 | 2.25 | -2.00 | — | 2.04 | 65.39% | -73.34% | -71.58% | -50.30% | -304.73% | -40.68% | 0.01 | -731.63 | 5.07 | 3.39 | 0.51 | -2623.00% | 4863.00% | 436.00% | -37.47% | -3.12 | -349.90% | 0.00% | 0.00% | 0.00% | -1.99 | -1.73 | 1.46 | -6.75 |
| LYRA | Lyra Therapeutics, Inc. | $1.01 | 1.79M | +2,414% | +280% | — | — | -6.69 | 53.92 | 407.49 | -10.27 | -49.59 | 53.92 | 100.00% | -6280.83% | -6090.94% | -184.99% | -1017.13% | -89.43% | 2.97 | — | 3.41 | 3.21 | 0.10 | 1349.00% | -154.00% | 1243.00% | -11.57% | -5.54 | -763.78% | 0.00% | 0.00% | 1.72% | -6.42 | -8.55 | 403.45 | -5.91 |
| MBIO | Mustang Bio, Inc. | $1.01 | 7.37M | — | — | — | — | -0.58 | -2.34 | — | -0.21 | — | -2.34 | 0.00% | — | — | 840.11% | 241.62% | -116.47% | -0.23 | 3249.00 | 0.68 | 0.57 | 0.40 | -5717.00% | — | -7699.00% | -125.80% | -0.90 | 169.70% | 6.74% | -3.90% | 31.27% | -0.19 | -0.27 | — | -65.53 |
| MRKR | Marker Therapeutics, Inc. | $1.48 | 15.98M | +3,230% | -2% | — | — | -1.26 | 0.73 | 2.04 | 0.51 | — | 0.73 | -104.33% | -168.69% | -162.82% | -65.81% | 1313.50% | -54.82% | 0.00 | — | 6.36 | 6.22 | 1.73 | -3834.00% | 9906.00% | -3364.00% | -81.00% | -3.15 | 1288.92% | 0.00% | 0.00% | 30.30% | 0.51 | 0.52 | -0.87 | -26.44 |
About Aptorum Group Limited
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
- CEO
- Chung Yuen Huen
- Employees
- 1
- Beta
- -0.09
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.88) − 1 = — (DCF, example).